<DOC>
	<DOCNO>NCT01466985</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , antiretroviral activity doravirine ( MK-1439 ) monotherapy antiretroviral therapy ( ART ) -naïve , HIV-1-infected participant .</brief_summary>
	<brief_title>A Study Doravirine ( MK-1439 ) Human Immunodeficiency Virus Type 1 ( HIV-1 ) -Infected Participants ( MK-1439-005 )</brief_title>
	<detailed_description />
	<criteria>Diagnosis HIV1infection ≥3 month prior screen Participants female partner ( ) childbearing potential must agree use medically acceptable method contraception study 90 day last dose study drug Body Mass Index ( BMI ) ≤35 kg/m^2 Other HIV infection , participant 's baseline health judge stable No clinically significant abnormality electrocardiogram ( ECG ) Participant ARTnaïve ( define never receive antiretroviral agent ≤30 consecutive day investigational antiretroviral agent ( exclude NonNucleoside Reverse Transcriptase Inhibitor [ NNRTI ] ) ≤60 consecutive day combination ART include NNRTI ) Participant willing receive ART duration treatment phase study . History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological ( outside HIV1 infection ) , renal , respiratory , genitourinary abnormality diseases History clinically significant neoplastic disease Participant use immune therapy agent immunosuppressive therapy within 1 month prior treatment study Participant one preexisting risk factor Torsades de Pointes ( New York Heart Association Functional Classification II IV heart failure , familial longQTsyndrome , uncorrected hypokalemia , QTcF &gt; 470 msec ) Participant require anticipated require chronic daily prescription medication Current ( active ) diagnosis acute hepatitis due cause History chronic Hepatitis C unless document cure and/or patient positive serologic test HCV negative HCV viral load . Positive Hepatitis B surface antigen Participant unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy ( St. John 's Wort [ Hypericum perforatum ] ) begin approximately 2 week ( 5 halflives ) prior administration initial dose study drug , throughout study , poststudy visit Participant consume excessive amount alcohol , define great 3 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day Participant consume excessive amount , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day Participant excessive smoker ( i.e. , 10 cigarettes/day ) unwilling restrict smoking ≤10 cigarette per day Major surgery , donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior prestudy ( screen ) visit Participation another investigational study within 4 week prior prestudy ( screen ) visit History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Current regular user ( include use illicit drug ) history drug ( include alcohol ) abuse within approximately 1 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>